EP
SKYE icon

Essential Partners’s Skye Bioscience SKYE Stock Holding History

Essential Partners’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$33 – 2809
2025
Q2 		$33 Buy
+1
New +$17 ﹤0.01% 2189

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's SKYE Position: Q3 2025 in Review

Essential Partners sold out of Skye Bioscience (SKYE) in Q3 2025, closing a stake of 1 share — an estimated $33 sold.

Essential Partners first reported a position in SKYE in Q2 2025 and held it in 1 quarter. The position peaked at $33 in Q2 2025. 52 funds tracked by Wall St. Rank hold SKYE as of Q3 2025.

  • Essential Partners reported no remaining Skye Bioscience position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 1 Skye Bioscience share in Q3 2025, an estimated $33.
  • Essential Partners first reported a position in Skye Bioscience in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Skye Bioscience position peaked at $33 in Q2 2025.
  • 52 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.